The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is characterized by deposition of amyloid-β (Aβ) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against Aβ to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal Aβ, and reduce soluble and insoluble Aβ in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain Aβ in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating-Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aducanumab (1) binds to 3-7 amino acids of Aβ, targeting soluble oligomers and insoluble fibrils.418,419”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [418]
In the citing paper
“Aducanumab has been tested in a phase II study, demonstrating its biological effect in terms of Aβ removal via PET with amyloid tracer [56].”
From Treatment of Alzheimer’s Disease: Beyond Symptomatic Therapies (2023) · cites this paper as [56]
In the citing paper
“Additionally, amyloid was cleared from the six cortical regions of interest, namely the frontal, parietal, lateral temporal, sensorimotor, anterior, and posterior cingulate areas [43].”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [43]
In the citing paper
“Studies have shown that amyloid deposition was reduced in all treatment groups at 26 weeks and further reduced by the end of the first year.”
From Clinical trials of new drugs for Alzheimer disease (2020) · cites this paper as [43]
In the citing paper
“Anti-Aβ immunotherapies have shown reductions in amyloid PET and several amyloid reducing therapies for AD use amyloid PET (or CSF) as a key endpoint [172, 173].”
From The use of neuroimaging techniques in the early and differential diagnosis of dementia (2023) · cites this paper as [173]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., Szoeke, C., Macaulay, S. L., Martins, R., Maruff, P., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70044-9 · Cited by 2,279
Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
Benilova, I., Karran, E., & De Strooper, B. (2012) · Nature Neuroscience · doi:10.1038/nn.3028 · Cited by 1,962
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960
Self-citation
Cited by
Items 801–900 of 1,043
A Concise Review on Oxidative Stress-Mediated Ferroptosis and Cuproptosis in Alzheimer’s Disease
Huang, X. (2023) · Cells · doi:10.3390/cells12101369 · Cited by 51
“In June 2021, the FDA controversially approved a monoclonal antibody drug called Aducanumab (marketed as Aduhelm) with marginal cognitive benefit [17], using its accelerated approval pathway.”
BackgroundImplications of the Approval of Lecanemab for Alzheimer Disease Patient Care
Knopman, D. S., & Hershey, L. A. (2023) · Neurology · doi:10.1212/wnl.0000000000207438 · Cited by 51
Overlapping Neuroimmune Mechanisms and Therapeutic Targets in Neurodegenerative Disorders
Marchi, F. D., Munitić, I., Vidatic, L., Papić, E., Rački, V., Nimac, J., Jurak, I., Novotni, G., Rogelj, B., Vuletić, V., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11102793 · Cited by 54
“…to bind the A β -42 species, reducing toxicity, preventing cell death, and restoring plasticity at the hippocampal level in animal models [173–175]. neuropathological studies [180], the vaccine Di ff erent A β -targeting monoclonal antibodies have been proposed in recent years for AD…”
BackgroundAlbertini, G., Zielonka, M., Cuypers, M., Snellinx, A., Xu, C., Poovathingal, S. K., Wojno, M., Davie, K., van Lieshout, V., Craessaerts, K., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02125-8 · Cited by 71
“For instance, while some studies report microglia accumulation around amyloid plaques after immunotherapy 5 , such clustering is also observed without the antibody treatment and does not necessarily result in Aβ-plaque removal.”
Cortical Superficial Siderosis in Different Types of Cerebral Small Vessel Disease
Wollenweber, F. A., Baykara, E., Zedde, M., Gesierich, B. G., Achmüller, M., Jouvent, É., Viswanathan, A., Ropele, S., Chabriat, H., Schmidt, R., et al. (2017) · Stroke · doi:10.1161/strokeaha.117.016833 · Cited by 49
Notch3ECD immunotherapy improves cerebrovascular responses in CADASIL mice
Ghezali, L., Capone, C., Baron‐Menguy, C., Ratelade, J., Christensen, S., Pedersen, L. Ø., Domenga, V., Pedersen, J. T., & Joutel, A. (2018) · Annals of Neurology · doi:10.1002/ana.25284 · Cited by 48
“The first mechanism involves antibody binding to deposited amyloid plaques, with subsequent microglial/macrophage activation around plaques and phagocytosis of existing plaques.(20,21) Notably, antibodies directed against deposited amyloid have shown dose-proportional effects on plaque clearance.”
BackgroundSabbagh, M. N., & Cummings, J. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12235 · Cited by 48
Liu, Y., Wang, J., Li, Q., Fowler, C. J., Zeng, F., Deng, J., Xu, Z., Zhou, H., Doecke, J. D., Villemagne, V. L., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb0457 · Cited by 53
Stefanovski, L., Meier, J. M., Pai, R. K., Triebkorn, P., Lett, T. A. P., Martin, L., Bülau, K., Hofmann‐Apitius, M., Solodkin, A., McIntosh, A. R., et al. (2021) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2021.630172 · Cited by 56
“…clinical trials testing substances such as anti-Amyloid-beta (Gilman et al., 2005; Lannfelt et al., 2008; Winblad et al., 2012; Farlow et al., 2015; Sevigny et al., 2016; Vandenberghe et al., 2017; Panza et al., 2019), tau-protein targeting (Yanamandra et al., 2015; Bachurin et al., 2017; Jadhav…”
BackgroundPromising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update
Park, S. A., Jang, Y. J., Kim, M. K., Lee, S. M., & Moon, S. Y. (2022) · Journal of Clinical Neurology · doi:10.3988/jcn.2022.18.4.401 · Cited by 47
NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load
Pohlkamp, T., Xian, X., Wong, C. H., Durakoglugil, M. S., Werthmann, G. C., Saido, T. C., Evers, B. M., White, C. L., Connor, J., Hammer, R. E., et al. (2021) · eLife · doi:10.7554/elife.72034 · Cited by 46
Zhao, P., Xu, Y., Fan, X., Li, L., Li, X., Arase, H., Tong, Q., Zhang, N., & An, Z. (2022) · mAbs · doi:10.1080/19420862.2022.2107971 · Cited by 51
8-Hydroxyquinolylnitrones as multifunctional ligands for the therapy of neurodegenerative diseases
Knez, D., Diez‐Iriepa, D., Chioua, M., Gottinger, A., Denic, M., Chantegreil, F., Nachon, F., Brazzolotto, X., Skrzypczak-Wiercioch, A., Meden, A., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.01.013 · Cited by 48
“(Z)-N-tert-Butyl-1-(2-chloro-8-methoxyquinolin-3-yl)methanimine oxide (9).”
Monoclonal Antibody Therapy in Alzheimer’s Disease
Neațu, M., Covaliu, A., Ioniță, I., Jugurt, A., Davidescu, E. I., & Popescu, B. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010060 · Cited by 48
Aggregation Mechanisms and Molecular Structures of Amyloid‐β in Alzheimer's Disease
Niu, Z., Gui, X., Feng, S., & Reif, B. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202400277 · Cited by 54
Specification of Physiologic and Disease States by Distinct Proteins and Protein Conformations
Jarosz, D. F., & Khurana, V. (2017) · Cell · doi:10.1016/j.cell.2017.10.047 · Cited by 49
Pradhan, N., Debnath, K., Mandal, S., Jana, N. R., & Jana, N. R. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00671 · Cited by 47
Recent advancements toward therapeutic vaccines against Alzheimer’s disease
Herline, K., Drummond, E., & Wisniewski, T. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1500905 · Cited by 44
Katsinelos, T., Tuck, B. J., Mukadam, A. S., & McEwan, W. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01139 · Cited by 48
Wei, M., Liu, Z., Liu, Y., Li, S., Hu, M., Yue, K., Liu, T., He, Y., Pi, Z., Liu, Z., et al. (2019) · Food & Function · doi:10.1039/c9fo00677j · Cited by 49
Novel Targets for Alzheimer's Disease: A View Beyond Amyloid
Ray, W. J., & Buggia-Prevot, V. (2021) · Annual Review of Medicine · doi:10.1146/annurev-med-052919-120219 · Cited by 43
Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain
Pardridge, W. M. (2020) · Frontiers in Medical Technology · doi:10.3389/fmedt.2020.602236 · Cited by 46
“However, the blood concentration of the antibody also increased at the higher IDs (138).”
BackgroundSerotonin and Melatonin Show Different Modes of Action on Aβ42 Protofibril Destabilization
Gong, Y., Zhan, C., Zou, Y. F., Qian, Z., Wei, G., & Zhang, Q. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00038 · Cited by 45
Young, C. B., Landau, S. M., Harrison, T. M., Poston, K. L., & Mormino, E. C. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118553 · Cited by 45
“…important for the integration of tau PET into linical trials, which has become commonplace in multiple high prole anti-amyloid trials investigating aducanamab ( Sevigny et al., 2016 ), olanezumab ( Siemers et al., 2016 ), lecanemab ( Swanson et al., 2021 ), nd donanamab ( Mintun et al., 2021 ).”
New Possibilities in the Therapeutic Approach to Alzheimer’s Disease
Doroszkiewicz, J., & Mroczko, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168902 · Cited by 51
“Firstly, animal model studies revealed that this antibody can significantly improve cognition and lower brain pathology by removing Aβ from the brain [49].”
BackgroundInfluentialBastrup, J., Hansen, K. H., Poulsen, T. B. G., Kastaniegaard, K., Asuni, A. A., Christensen, S., Belling, D., Helboe, L., Stensballe, A., & Volbracht, C. (2021) · Journal of Alzheimer's Disease · doi:10.3233/jad-200715 · Cited by 46
Meilandt, W. J., Maloney, J. A., Imperio, J., Lalehzadeh, G., Earr, T., Crowell, S., Bainbridge, T. W., Lu, Y., Ernst, J. A., Fuji, R. N., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0553-5 · Cited by 45
Marino, C., Perez‐Corredor, P., O'Hare, M., Heuer, A., Chmielewska, N., Gordon, H., Chandrahas, A. S., Gonzalez‐Buendia, L., Delgado‐Tirado, S., Doan, T. H., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13436 · Cited by 45
Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders
Golde, T. E. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.027 · Cited by 45
Microtechnologies for single-cell and spatial multi-omics
Deng, Y., Bai, Z., & Fan, R. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00084-y · Cited by 46
Tondo, G., Marchi, F. D., Bonardi, F., Menegon, F., Verrini, G., Aprile, D., Anselmi, M., Mazzini, L., & Comi, C. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113098 · Cited by 46
“Transgenic animal model studies first provided evidence of aducanumab’s benefit in entering the brain, selectively binding aggregated A β forms while showing low affinity for soluble monomers and reducing A β load in a dose-dependent manner [132–134].”
BackgroundFocused ultrasound as a novel strategy for Alzheimer disease therapeutics
Meng, Y., Volpini, M., Black, S. E., Lozano, A. M., Hynynen, K., & Lipsman, N. (2017) · Annals of Neurology · doi:10.1002/ana.24933 · Cited by 45
“Patients with prodromal or mild AD had reduced soluble and insoluble Ab on amyloid imaging, in a dose-responsive fashion, which was further linked to a slowing of cognitive decline.(18) The challenges of immunotherapy include the timing of administration as well as limited bioavailability due to incomplete passage acr…”
BackgroundAlzheimer’s disease: amyloid-based pathogenesis and potential therapies
Zhou, Y., Sun, Y., Ma, Q., & Liu, Y. (2018) · Cell Stress · doi:10.15698/cst2018.07.143 · Cited by 53
Yang, Z., Song, Q., Cao, Z., Yu, G., Liu, Z., Tan, Z., & Deng, Y. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115374 · Cited by 45
Azam, S., Haque, M. E., Kim, I., & Choi, D. (2021) · Cells · doi:10.3390/cells10010150 · Cited by 51
Xiao, Y. M., Dai, Y., Li, L., Geng, F., Xu, Y., Wang, J., Wang, S., & Zhao, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111651 · Cited by 46
Wan, J., Zhou, S., Mea, H. J., Guo, Y., Ku, H., & Urbina, B. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00480 · Cited by 54
Optogenetics: implications for Alzheimer’s disease research and therapy
Mirzayi, P., Shobeiri, P., Kalantari, A., Perry, G. L., & Rezaei, N. (2022) · Molecular Brain · doi:10.1186/s13041-022-00905-y · Cited by 51
“The recent approval of Aducanumab reignited the interest around novel therapeutic approaches, as it marks the first approved disease-modifying therapy for AD [145, 146].”
BackgroundGenetic risk factors for Alzheimer disease: emerging roles of microglia in disease pathomechanisms
Takatori, S., Wang, W., Iguchi, A., & Tomita, T. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-05542-4_5 · Cited by 44
Knockdown of Amyloid Precursor Protein: Biological Consequences and Clinical Opportunities
Gabriele, R. M. C., Abel, E., Fox, N. C., Wray, S., & Arber, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.835645 · Cited by 44
Lipid-Based Drug Delivery Systems in Regenerative Medicine
Filipczak, N., Yalamarty, S. S. K., Li, X., Khan, M. M., Parveen, F., & Torchilin, V. P. (2021) · Materials · doi:10.3390/ma14185371 · Cited by 47
“Hyperphosphorylated tau that generates neurofibrillary tangles (NFTs) leads to synaptic dysfunction [96,97].”
BackgroundA human antibody against pathologic IAPP aggregates protects beta cells in type 2 diabetes models
Wirth, F., Heitz, F. D., Seeger, C., Combaluzier, I., Breu, K., Denroche, H. C., Thévenet, J., Osto, M., Arosio, P., Kerr-Conte, J. A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41986-0 · Cited by 53
Self-citationSharma, H., & Chandra, P. (2023) · International Journal of Pharmaceutical Investigation · doi:10.5530/ijpi.14.1.15 · Cited by 50
Liu, N., Liang, X., Chen, Y., & Xie, L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102199 · Cited by 53
Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit
Høilund‐Carlsen, P. F., Alavi, A. A., Barrio, J. R., Castellani, R. J., Costa, T., Herrup, K., Kepp, K. P., Neve, R. L., Perry, G. L., Revheim, M.-E. R., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102348 · Cited by 47
Yaribash, S., Mohammadi, K., & Sani, M. A. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01544-2 · Cited by 46
“MEDI1341 and Lu AF82422 are also of humanized antibodies, and PRX002/prasinezumab is a humanized version of murine based antibodies (Bergström et al. 2016; Braczynski et al. 2017; Schofield et al. 2019; Sevigny et al. 2016).”
Modulation of innate immunity of patients with Alzheimer's disease by omega‐3 fatty acids
Fiala, M., Kooij, G., Wagner, K., Hammock, B., & Pellegrini, M. (2017) · The FASEB Journal · doi:10.1096/fj.201700065r · Cited by 44
Cabral, C. M., McGovern, K. E., MacDonald, W. R., Franco, J., & Koshy, A. A. (2017) · ASN NEURO · doi:10.1177/1759091417724915 · Cited by 47
Vaccination strategies in tauopathies and synucleinopathies
Braczynski, A. K., Schulz, J. B., & Bach, J. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14207 · Cited by 45
“In a first dose-finding phase Ib/IIa study in patients with prodromal to mild AD, aducanumab led to a concentration-dependent reduction of cerebral Ab plaque load as measured by florbetapir PET over a time period of 54 weeks (Sevigny et al. 2016).”
MethodGustafsson, S., Gustavsson, T., Roshanbin, S., Hultqvist, G., Hammarlund-Udenaes, M., Sehlin, D., & Syvänen, S. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.09.001 · Cited by 44
The application of positron emission tomography (PET) imaging in CNS drug development
Suridjan, I., Comley, R. A., & Rabiner, E. A. (2018) · Brain Imaging and Behavior · doi:10.1007/s11682-018-9967-0 · Cited by 45
Javed, I., He, J., Käkinen, A., Faridi, A., Yang, W. L., Davis, T. P., Ke, P. C., & Chen, P. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b19506 · Cited by 48
Innate Immunity and Cell Death in Alzheimer’s Disease
Lee, S., Cho, H.-J., & Ryu, J.-H. (2021) · ASN Neuro · doi:10.1177/17590914211051908 · Cited by 45
Yan, C., Wang, C., Shao, X., Shu, Q., Hu, X., Guan, P., Teng, Y., & Cheng, Y. (2021) · Materials Today Bio · doi:10.1016/j.mtbio.2021.100167 · Cited by 52
Knecht, L. H., Folke, J., Dodel, R. C., Ross, J. A., & Albus, A. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01288-7 · Cited by 48
p38 MAPK Is a Major Regulator of Amyloid Beta-Induced IL-6 Expression in Human Microglia
Lin, H., Dixon, S. G., Hu, W., Hamlett, E. D., Jin, J., Ergul, A., & Wang, G. Y. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02909-0 · Cited by 45
“AD patients who received aducanumab treatment displayed a dose- and time-dependent reduction of Aβ plaques, while patients in the control arm did not show such changes [64, 65].”
BackgroundYarbro, J. M., Shrestha, H. K., Wang, Z., Zhang, X., Zaman, M., Chu, M., Wang, X., Yu, G., & Peng, J. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00874-5 · Cited by 46
“Recently, the U.S. Food and Drug Administration (FDA) approved several Aβ-targeting treatments, including aducanumab [2], lecanemab [3], and donanemab [4].”
Abnormal Homocysteine Metabolism: An Insight of Alzheimer’s Disease from DNA Methylation
Pi, T., Liu, B., & Jing-shan, S. (2020) · Behavioural Neurology · doi:10.1155/2020/8438602 · Cited by 47
“A series of landmark studies states that the role of targeting Aβ peptide in the treatment of AD will delay the progression of the disease [28, 29] by inhibiting monomer aggregation and preventing the formation of toxic species [30].”
BackgroundFeasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy
Song, M., Scheifele, M., Barthel, H., van Eimeren, T., Beyer, L., MAREK, K. L., Eckenweber, F., Palleis, C., Kaiser, L., Finze, A., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05391-3 · Cited by 50
“including the β-amyloid antibody aducanumab [27] and the beta-secretase inhibitors verubecestat and lanabecestat [28].”
BackgroundAutomated detection of cerebral microbleeds on T2*-weighted MRI
Chesebro, A. G., Amarante, E., Lao, P. J., Meier, I. B., Mayeux, R. P., & Brickman, A. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-83607-0 · Cited by 44
Amyloid-β Oligomers: Multiple Moving Targets
Shea, D. W., & Daggett, V. (2022) · Biophysica · doi:10.3390/biophysica2020010 · Cited by 46
Deep learning-driven adaptive optics for single-molecule localization microscopy
Zhang, P., Ma, D., Cheng, X., Tsai, A. P., Tang, Y., Gao, H.-C., Fang, L., Bi, C., Landreth, G. E., Chubykin, A. A., et al. (2023) · Nature Methods · doi:10.1038/s41592-023-02029-0 · Cited by 42
“The 3D structures of amyloid-β (Aβ) fibrils are a focus of interest in the studies of Alzheimer’s disease and are of particular importance with the success of amyloid-directed therapeutics 53,54 .”
BackgroundNeurotechnological Approaches to the Diagnosis and Treatment of Alzheimer’s Disease
Ning, S., Jorfi, M., Patel, S. R., Kim, D. Y., & Tanzi, R. E. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.854992 · Cited by 49
Sun, X., Yu, X., Zhu, J., Li, L.-J., Zhang, L., Huang, Y., Liu, D., Ji, M., Sun, X., Zhang, L. L., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01273-8 · Cited by 52
“Recently, antibodies targeting Aβ aggregates such as aducanumab and lecanemab showed some beneficial effects in rescuing cognitive deficits, but they still exhibited low efficacy.(15,16) Thus, the underlying mechanism of the failures and low efficacy in clinical trials should be urgently investigated for the developme…”
BackgroundZhang, M., Wang, W., Ye, Q., Fu, Y., Li, X., Yang, K., Gao, F., Zhou, A., Wei, Y., Tian, S., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01384-0 · Cited by 44
Alzheimer’s Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?
Høilund‐Carlsen, P. F., Alavi, A. A., Castellani, R. J., Neve, R. L., Perry, G. L., Revheim, M.-E. R., & Barrio, J. R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073892 · Cited by 47
Unraveling Alzheimer’s: the promise of aducanumab, lecanemab, and donanemab
Ameen, T. B., Kashif, S. N., Abbas, S. M. I., Babar, K., Ali, S. M. S., & Raheem, A. (2024) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-024-00845-5 · Cited by 49
Multi-functional role of apolipoprotein E in neurodegenerative diseases
Islam, S., Noorani, A. A., Sun, Y., Michikawa, M., & Zou, K. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1535280 · Cited by 47
Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
Dekker, A. D., Fortea, J., Blesa, R., & De Deyn, P. P. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.02.006 · Cited by 41
“Although the process of neurodegeneration cannot yet be prevented or stopped, a recently completed clinical trial (phase Ib) using immunotherapy with aducanumab reported a dose- and time-dependent reduction of Ab plaques in the brain of patients with prodromal or mild AD, indicating the potential of this human monoclo…”
BackgroundHa, H.-J., Kang, D. W., Kim, H.-M., Kang, J.-M., Ann, J., Hyun, H. J., Lee, J. H., Kim, S. H., Kim, H., Choi, K., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00844 · Cited by 43
The past, present, and future of disease-modifying therapies for Alzheimer’s disease
Suzuki, K., Iwata, A., & Iwatsubo, T. (2017) · Proceedings of the Japan Academy Series B · doi:10.2183/pjab.93.048 · Cited by 48
Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab
Liu, E., Wang, D., Sperling, R., Salloway, S., Fox, N. C., Blennow, K., Scheltens, P., Schmidt, M. E., Streffer, J., Novak, G., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005060 · Cited by 44
Self-citationChen, Y., Chen, Z., Sun, Y., Lei, J., & Wei, G. (2018) · Nanoscale · doi:10.1039/c8nr01041b · Cited by 43
Iturria-Medina, Y., Carbonell, F. M., & Evans, A. C. (2018) · NeuroImage · doi:10.1016/j.neuroimage.2018.06.028 · Cited by 41
Anti-Aβ Antibodies and Cerebral Amyloid Angiopathy Complications
Chantran, Y., Capron, J., Alamowitch, S., & Aucouturier, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01534 · Cited by 42
“In particular, while none of the placebo-treated subjects had cortical superficial siderosis, 9 Aducanumab-treated patients presented with such manifestations (75).”
BackgroundGupta, S., & Dasmahapatra, A. K. (2019) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp04162a · Cited by 44
Tau and DNA Damage in Neurodegeneration
Colnaghi, L., Rondelli, D., Muzi-Falconi, M., & Sertic, S. (2020) · Brain Sciences · doi:10.3390/brainsci10120946 · Cited by 43
Screening for Early-Stage Alzheimer’s Disease Using Optimized Feature Sets and Machine Learning
Kleiman, M. J., Barenholtz, E., Galvin, J. E., & Initiative, F. T. A. D. N. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201377 · Cited by 44
Day, G. S., Scarmeas, N., Dubinsky, R., Coerver, K., Mostacero, A., West, B., Wessels, S. R., & Armstrong, M. J. (2022) · Neurology · doi:10.1212/wnl.0000000000200176 · Cited by 39
RetractedOptimal anti-amyloid-beta therapy for Alzheimer’s disease via a personalized mathematical model
Hao, W., Lenhart, S., & Petrella, J. R. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010481 · Cited by 57
“The extent of these gaps in the blood vessel walls is likely related to the overall amyloid burden of the patient and the rate of removal of amyloid, the latter a function of the drug dosage [21].”
BackgroundLi, Z., Zheng, G., Wang, N., Liang, H., Li, C., Wang, Y., Cui, Y., & Yang, L. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c06809 · Cited by 42
Evaluating Causal Effects of Gut Microbiome on Alzheimer's Disease
Zhao, Q. S., Baranova, A. V., Cao, H., & Zhang, F. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.113 · Cited by 45
“lzheimer’s disease (AD) refers to the specific onset and course of age-related cognitive and functional decline (1).”
Paolis, M. L. D., Paoletti, I., Zaccone, C., Capone, F., D’Amelio, M., & Krashia, P. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00423-y · Cited by 49
“…potential candidates [12, 13], this effort resulted in the recent FDA approval of two anti-Aβ antibodies, adu-canumab and lecanemab, based on imaging data showing reduction in amyloid burden and clinical results indicating a slowing-down of cognitive decline and improvement in daily living [14–16].”
BackgroundSuzuki, N., Hatta, T., Ito, M., & Kusakabe, K. (2024) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c24-00069 · Cited by 50
Ali, J., Choe, K., Park, J. S., Park, H. Y., Kang, H., Park, T. J., & Kim, M.-O. (2024) · Antioxidants · doi:10.3390/antiox13070862 · Cited by 44
Belostozky, A., Richman, M., Lisniansky, E., Tovchygrechko, A., Chill, J. H., & Rahimipour, S. (2018) · Chemical Communications · doi:10.1039/c8cc01233d · Cited by 41
Boche, D., & Nicoll, J. A. R. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12642 · Cited by 42
Schwarz, A. J. (2021) · Neurotherapeutics · doi:10.1007/s13311-021-01027-4 · Cited by 42
“Some recent anti-amyloid treatments have demonstrated in clinical trials that amyloid load as detected by PET can be reduced to levels far below baseline in many trial participants, and in some cases reduced below the level used as a threshold for amyloid positivity [90].”
BackgroundInfluentialHardy, K. S., Tessmer, M. H., Frank, D. W., & Audia, J. P. (2021) · Toxins · doi:10.3390/toxins13120880 · Cited by 43
Wang, H., Chen, M., Sun, Y., Xu, L. Y., Li, F., & Han, J. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c03623 · Cited by 41
Zhang, Q., Zhao, W., Hou, Y., Song, X., Yu, H., Tan, J., Zhou, Y., & Zhang, H. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14132 · Cited by 40
Neuroprotective Effects of PARP Inhibitors in Drosophila Models of Alzheimer’s Disease
Maggiore, A., Casale, A. M., Toscanelli, W., Cappucci, U., Rotili, D., Grieco, M., Gagné, J.-P., Poirier, G. G., d’Erme, M., & Piacentini, L. (2022) · Cells · doi:10.3390/cells11081284 · Cited by 40
Gehlot, P., Kumar, S., Vyas, V. K., Choudhary, B. S., Sharma, M., & Malik, R. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.117047 · Cited by 47
Fast and Accurate Amyloid Brain PET Quantification Without MRI Using Deep Neural Networks
Kang, S. K., Kim, D., Shin, S. A., Kim, Y. K., Choi, H., & Lee, J. S. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264414 · Cited by 43
“Monoclonal antibodies such as aducanumab and donanemab are emerging as AD treatment drugs that target aggregated amyloid b to reduce its buildup in the brain (20,21).”
BackgroundTherapeutic Potential of Targeting Mitochondria for Alzheimer’s Disease Treatment
Atlante, A., Amadoro, G., Latina, V., & Valenti, D. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11226742 · Cited by 41
“However, at present, neuroscientists are still skeptical because there is no absolute certainty that the reduction in Aβ plaques can be correlated with actual patient improvement [38,39].”
Sun, Y., Yan, C., He, L., Xiang, S., Wang, P., Li, Z., Chen, Y., Zhao, J., Yuan, Y., Wang, W., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101899 · Cited by 45
Scuteri, D., Rombolà, L., Tridico, L., Mizoguchi, H., Watanabe, C., Sakurada, T., Sakurada, S., Corasaniti, M. T., Bagetta, G., & Morrone, L. A. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180307115546 · Cited by 40
Jin, Y., Sun, Y., Lei, J., & Wei, G. (2018) · Physical Chemistry Chemical Physics · doi:10.1039/c8cp01631c · Cited by 41
Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer’s Disease
Vander Zanden, C. M., & Chi, E. Y. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.024 · Cited by 41
Bullain, S., & Doody, R. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15023 · Cited by 38
“ARIA incidence for these N-terminus anti-amy-loid antibodies increased in a dose-dependent and APOE ε 4-de-pendent manner (Ostrowitzki et al., 2017; Salloway et al., 2014; Sevigny et al., 2016).”
Influential
Metadata
- Authors
- Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O’Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M. S., Quintero-Monzon, O., Scannevin, R. H., Arnold, H. M., Engber, T., Rhodes, K., Ferrero, J., Hang, Y., Mikulskis, A., Grimm, J., Hock, C., Nitsch, R. M., & Sandrock, A.
- Affiliations
- Biogen (United States) (US)
- Light Chain Bioscience (Switzerland) (CH)
- Butler Hospital (US)
- University of Zurich (CH)
- Corresponding author
- Sandrock, Alfred
- ORCID
- Venue
- Nature
- Published
- 2016-08-31
- Volume
- 537
- Issue
- 7618
- Pages
- 50-56
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2510806376
- Cited by
- 3,059
- References
- 42
- Citations by year
- 2026: 186 · 2025: 340 · 2024: 389 · 2023: 332 · 2022: 416 · 2021: 326 · 2020: 263 · 2019: 231 · 2018: 268 · 2017: 252 · 2016: 52
- FWCI
- 214.30
- Type
- journal article
- Language
- en
- Update notices
- addendum (2017-06-22)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- Biogen
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- aducanumab, Alzheimer's disease, amyloid plaques, anti-amyloid monoclonal antibodies, immunotherapy, amyloid hypothesis, transgenic mouse model, prodromal Alzheimer's disease, clinical deterioration, amyloid-related imaging abnormalities, drug safety and tolerability
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Animals, Brain, Disease Models, Animal, Dose-Response Relationship, Drug, Female, Humans, Male, Mice, Transgenic, Middle Aged, Models, Biological, Solubility, Amyloid beta-Peptides, Clinical Trials, Phase III as Topic, Mice, Plaque, Amyloid, Antibodies, Monoclonal, Humanized, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.